Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%

In This Article:

Key Insights

  • Significant control over Kiora Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions

  • A total of 7 investors have a majority stake in the company with 53% ownership

  • Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business

To get a sense of who is truly in control of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 39% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

Hedge funds, on the other hand, account for 31% of the company's stockholders.

Let's delve deeper into each type of owner of Kiora Pharmaceuticals, beginning with the chart below.

Check out our latest analysis for Kiora Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Kiora Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Kiora Pharmaceuticals already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Kiora Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 31% of Kiora Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Lincoln Park Capital, LLC is currently the largest shareholder, with 8.9% of shares outstanding. The second and third largest shareholders are Rosalind Advisors, Inc. and Aigh Capital Management, LLC, with an equal amount of shares to their name at 8.8%.

We did some more digging and found that 7 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.